DUBLIN–(BUSINESS WIRE)–The “Global Oncology Diagnostics in IVD Growth Opportunities” report has been added to ResearchAndMarkets.com’s offering.
The global oncology diagnostics in IVD market is poised for substantial growth, primarily propelled by the rising cancer incidence rates, advancements in diagnostic test technologies, an upsurge in screening procedures, and proactive government initiatives.
The market’s competitive landscape has prompted leading companies to make substantial investments in research and development, aimed at introducing novel diagnostic tests that offer enhanced accuracy and insights.
The burgeoning field of personalized medicine is rapidly gaining momentum, striving to customize cancer treatment approaches according to the unique requirements of individual patients. This progress is greatly facilitated by the evolution of cutting-edge diagnostic technologies designed to identify genetic anomalies responsible for driving cancer progression.
At the core of oncology diagnostics lies genomic profiling, a technique that enables the precise detection of mutations and variations in genes linked to cancer. This enables healthcare practitioners to fine-tune treatment plans based on genetic insights, leading to better treatment outcomes and the ability to predict the prognosis of cancer patients.
As these diagnostic tools continue to evolve, they empower medical professionals to make informed decisions that can significantly impact patient care and management.
Growth Opportunities
Growing Trend of Oncology Screening
Advanced, Integrated Diagnostics Labs
Increased Adoption of Liquid Biopsy Testing
Smart Diagnostics with AI
Unlocking CDx Opportunities in APAC
Unleashing Opportunities in Lung Cancer Diagnostics and Screening
A selection of companies mentioned in this report includes
Abbott Laboratories
Genomic Health
Guardant Health
Illumina
Invitae Corporation
Myriad Genetics
Natera
PerkinElmer
QIAGEN
Roche Diagnostics
Key Topics Covered:
1. Strategic Imperatives
Why is it Increasingly Difficult to Grow?
The Strategic Imperative
The Impact of the Top 3 Strategic Imperatives on the Global Oncology Diagnostics in IVD Industry
Growth Opportunities Fuel the Growth Pipeline Engine
2. Growth Opportunity Analysis
Scope of the Study
Segmentation by Test Type
Segmentation by Cancer Type
Segmentation by Application
3. Oncology Diagnostics in IVD: An Overview
Patient Care Continuum
Role of Oncology Diagnostics in Precision Medicine
The Role of Diagnostics is Crucial in the Evolving Precision Medicine Ecosystem
Trends Driving Cancer Testing
4. Oncology Diagnostics in IVD: Market Dynamics
Growth Metrics
Growth Drivers
Growth Restraints
Key Oncology Diagnostics Opportunities and the Impact on Business Dynamics
5. Oncology Diagnostics in IVD: Market Size and Forecast
Oncology Incidence Rate
Age-standardized Global Incidence Rates Per Sex – Top 10 Cancers
Forecast Assumptions
Revenue Forecast
Revenue Forecast Analysis
Revenue Forecast by Region
Revenue Forecast Analysis by Region
HRSA’s Investment in the Accelerating Cancer Screening Program (the United States)
Revenue Forecast by Test Type
Revenue Forecast Analysis by Test Type
Revenue Forecast by Cancer Type
Revenue Forecast Analysis by Cancer Type
Overview of Oncology Diagnostic Test Reimbursement by Region
Revenue Forecast by Application
Revenue Forecast Analysis by Application
6. Competitive Analysis
Competitive Environment
Key Competitors
Revenue Share by Tier
Companies to Watch – QIAGEN
Companies to Watch – Roche Diagnostics
Companies to Watch – Guardant Health
Companies to Watch – Myriad Genetics
Companies to Watch – Genomic Health
Companies to Watch – PerkinElmer
Companies to Watch – Invitae Corporation
Companies to Watch – Abbott Laboratories
Companies to Watch – Illumina
Companies to Watch – Natera
Global Oncology Diagnostics Market: Notable Activities
Competitive Mapping by Application
Oncology Diagnostic Participants: Competitive Benchmarking
Global Oncology Diagnostics Companies: Strategic Imperatives
7. Companion Diagnostics
CDx Overview
CDx Market Trends
CDx Global Reimbursement Overview
CDx Reimbursement Challenges
CDx FDA Approvals for Oncology Drugs and Biomarkers
CDx Targets by Company
Companion Diagnostic Partnerships
List of FDA-cleared/approved Companion Diagnostic IVD Devices
8. Liquid Biopsy
Liquid Biopsy: A Step Ahead in Biomarker Analysis
Potential of Liquid Biopsies to Improve Screening and Triage Pathways
miRNAs as Potential Cancer Biomarkers
Liquid Biopsy Companies in the Industry
Liquid Biopsy Regulatory Landscape
FDA-approved Liquid Biopsy Tests
Liquid Biopsy Technology and Recent Developments
Advancing Liquid Biopsies: Embracing Multiomics for Comprehensive Insights
Liquid Biopsy Market Opportunities
Liquid Biopsy Commercialization
For more information about this report visit https://www.researchandmarkets.com/r/im9cov
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
